Staging and Staging Errors in Bladder Cancer

European Urology, Supplements

Volumn 9, Issue 1, 2010, Pages 2-9

  Bostrom, Peter J ^a   van Rhijn, Bas W G ^a   Fleshner, Neil ^a   Finelli, Antonio ^a   Jewett, Michael ^a   Thoms, John ^a   Hanna, Sally ^a   Kuk, Cynthia ^a   Zlotta, Alexandre R ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bladder cancer; CT; Imaging; MRI; PET; Staging; Transurethral resection

Indexed keywords

FLUORODEOXYGLUCOSE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

BLADDER CANCER; BLADDER SURGERY; CANCER STAGING; CARCINOMA IN SITU; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; NOMOGRAM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SURGICAL APPROACH; URINARY TRACT CANCER;

EID: 77549086840     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2010.01.005     Document Type: Review

References (74)

1. van Rhijn B.W.G., Burger M., Lotan Y., et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56 (2009) 430-442
2. Shariat S.F., Palapattu G.S., Karakiewicz P., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51 (2007) 137-151 discussion 149-51
3. Sylvester R., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477 discussion 475-7
4. Ooms E., Anderson W., Alons C., Boon M., and Veldhuizen R. Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol 14 (1983) 140-143
5. MacLennan G.T., Kirkali Z., and Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 51 (2007) 889-898
6. May M, Brookman-Amissah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol. In press. doi:10.1016/j.eururo.2009.03.052.
7. van Rhijn BWG, van Leenders GJLH, Ooms BCM, et al. The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol. In press. doi:10.1016/j.eururo.2009.09.022.
8. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
9. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 (2005) 4-34
10. Younes M., Sussman J., and True L. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 66 (1990) 543-548
11. Holmäng S., Hedelin H., Anderström C., Holmberg E., and Johansson S. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 157 (1997) 800-803 discussion 804
12. Orsola A., Trias I., Raventós C., et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 48 (2005) 231-238 discussion 238
13. Cheng L., Neumann R., Weaver A., Spotts B., and Bostwick D. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 17 (1999) 3182-3187
14. van der Aa M.N., van Leenders G.J., Steyerberg E.W., et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol 36 (2005) 981-986
15. Van Rhijn B., Van Der Kwast T.D.K., et al. Impact of sub-stage and pathology review on the clinical outcome of pT1 bladder cancer. Paper presented at: Annual European Association of Urology Congress. March 17-21, Stockholm, Sweden (2009)
16. Yu R., Stein J., Cai J., et al. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 176 (2006) 493-498 discussion 498-9
17. Boudreaux K.J., Clark P., Lowrance W., et al. Comparison of American Joint Committee on Cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol 181 (2009) 540-545 discussion 546
18. Cheng L., Neumann R., Scherer B., et al. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. Cancer 85 (1999) 2638-2647
19. Bastian P., Hutterer G., Shariat S., et al. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. BJU Int 101 (2008) 450-454
20. Quek M., Stein J., Clark P., et al. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol 171 (2004) 640-645
21. Boudreaux K.J., Chang S., Lowrance W., et al. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer 115 (2009) 770-775
22. Liedberg F., and Månsson W. Lymph node metastasis in bladder cancer. Eur Urol 49 (2006) 13-21
23. Herr H. Superiority of ratio based lymph node staging for bladder cancer. J Urol 169 (2003) 943-945
24. Stein J., Cai J., Groshen S., and Skinner D. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol 170 (2003) 35-41
25. Kassouf W., Agarwal P., Herr H., et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 26 (2008) 121-126
26. Stephenson A, Gong M, Campbell S, Fergany A, Hansel D. Aggregate lymph node metastasis diameter and survival after radical cystectomy for invasive bladder cancer. Urology. In press.
27. Babjuk M. Transurethral resection of non-muscle-invasive bladder cancer. Eur Urol Suppl 8 (2009) 542-548
28. Herr H., and Donat S. Quality control in transurethral resection of bladder tumours. BJU Int 102 (2008) 1242-1246
29. Cauberg E., de la Rosette J., and de Reijke T. How to improve the effectiveness of transurethral resection in nonmuscle invasive bladder cancer?. Curr Opin Urol 19 (2009) 504-510
30. Lerner S., Colen J., and Shen S. Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma. Curr Opin Urol 18 (2008) 508-512
31. Jocham D., Stepp H., and Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol 53 (2008) 1138-1150
32. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174 (2005) 862-866 discussion 866
33. Fradet Y., Grossman H., Gomella L., et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 178 (2007) 68-73 discussion 73
34. Naselli A., Introini C., Bertolotto F., Spina B., and Puppo P. Narrow band imaging for detecting residual/recurrent cancerous tissue during second transurethral resection of newly diagnosed non-muscle-invasive high-grade bladder cancer. BJU Int 105 (2010) 208-211
35. Sonn G., Jones S., Tarin T., et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol 182 (2009) 1299-1305
36. Goh A., Tresser N., Shen S., and Lerner S. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology 72 (2008) 133-137
37. Schwaibold H., Sivalingam S., May F., and Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int 97 (2006) 1199-1201
38. Han K., Joung J., Cho K., et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol 22 (2008) 2699-2704
39. Divrik T., Yildirim U., Eroǧlu A., Zorlu F., and Ozen H. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?. J Urol 175 (2006) 1258-1261
40. Herr H., and Donat S. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 97 (2006) 1194-1198
41. Ng C. Radiologic diagnosis and staging of renal and bladder cancer. Semin Roentgenol 41 (2006) 121-138
42. Vikram R., Sandler C., and Ng C. Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract. AJR Am J Roentgenol 192 (2009) 1481-1487
43. Vikram R., Sandler C., and Ng C. Imaging and staging of transitional cell carcinoma: part 2, upper urinary tract. AJR Am J Roentgenol 192 (2009) 1488-1493
44. Bartsch G.C., Kuefer R., Gschwend J.E., et al. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol 51 (2007) 690-698 discussion 697-8
45. Jager G., Barentsz J., Oosterhof G., Witjes J., and Ruijs S. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 167 (1996) 1503-1507
46. Swinnen G., Maes A., Pottel H., et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 57 (2010) 641-647
47. Kibel A., Dehdashti F., Katz M., et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27 (2009) 4314-4320
48. Deserno W., Harisinghani M., Taupitz M., et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 233 (2004) 449-456
49. Harisinghani M., Barentsz J., Hahn P., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499
50. Thoeny H.C., Triantafyllou M., Birkhaeuser F.D., et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 55 (2009) 761-769
51. Sherif A., Garske U., de la Torre M., and Thörn M. Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancer. Eur Urol 50 (2006) 83-91
52. Stenzl A., Cowan N.C., De Santis M., et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 55 (2009) 815-825
53. Brismar J, Gustafson T. Bone scintigraphy in staging of bladder carcinoma. Acta Radiol, 29; 251-2.
54. Lauenstein T., Goehde S., Herborn C., et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 233 (2004) 139-148
55. Lotan Y., Gupta A., Shariat S., et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23 (2005) 6533-6539
56. Kunju L., You L., Zhang Y., et al. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 180 (2008) 1928-1932 discussion 1932
57. Karakiewicz P., Shariat S., Palapattu G., et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 176 (2006) 1354-1361 discussion 1361
58. Margel D., Harel A., Yossepowitch O., and Baniel J. A novel algorithm to improve pathologic stage prediction of clinically organ-confined muscle-invasive bladder cancer. Cancer 115 (2009) 1459-1464
59. Herr H., Dotan Z., Donat S., and Bajorin D. Defining optimal therapy for muscle invasive bladder cancer. J Urol 177 (2007) 437-443
60. Eble J., Sauter G., Epstein J., and Sesterhenn I. The World Health Organization classification of tumors of the urinary system and male genital system (2004), IARC Press, Lyon, France
61. Mostofi F, Sobin L, Torloni H. Histological typing of urinary bladder tumors. In: International classification of tumors. 1st ed. Geneva, Switzerland: World Health Organization; 1973.
62. In: Sobin D., and Wittekind C. (Eds). TNM classification of malignant tumors. ed 6 (2002), Wiley-Liss, New York, NY 199-202
63. Paik M., Scolieri M., Brown S., Spirnak J., and Resnick M. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 163 (2000) 1693-1696
64. Yaman O., Baltaci S., Arikan N., Yilmaz E., and Gögüs O. Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. Br J Urol 78 (1996) 197-200
65. Kim B., Semelka R., Ascher S., et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 193 (1994) 239-245
66. Tanimoto A., Yuasa Y., Imai Y., et al. Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT. Radiology 185 (1992) 741-747
67. Hayashi N., Tochigi H., Shiraishi T., Takeda K., and Kawamura J. A new staging criterion for bladder carcinoma using gadolinium-enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography. BJU Int 85 (2000) 32-36
68. Tekes A., Kamel I., Imam K., et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol 184 (2005) 121-127
69. Watanabe H., Kanematsu M., Kondo H., et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value?. AJR Am J Roentgenol 192 (2009) 1361-1366
70. Hofer C., Kübler H., Hartung R., Breul J., and Avril N. Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol 40 (2001) 481-487
71. Barentsz J., Witjes J., and Ruijs J. What is new in bladder cancer imaging. Urol Clin North Am 24 (1997) 583-602
72. Husband J. Computer tomography and magnetic resonance imaging in the evaluation of bladder cancer. J Belge Radiol 78 (1995) 350-355
73. Drieskens O., Oyen R., Van Poppel H., et al. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 32 (2005) 1412-1417
74. Picchio M., Treiber U., Beer A., et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 47 (2006) 938-944